pipette
ESEspañol

A novel 5-HT2A receptor-linked signalling pathway involving NAADP-mediated lysosomal Ca2+ release

A. L. Ippolito, A. Galione, G. Gilmour, G. C. Churchill, T. Sharp

Preprint

In the authors' words

Currently there is major research interest in the therapeutic potential of serotonergic psychedelic drugs across a range of neuropsychiatric disorders1-3. Such drugs exert psychedelic and neuroplastic effects, both likely linked to therapeutic outcomes, via agonist action at the 5-HT2A receptor4-7. This receptor is assumed to generate downstream intracellular signalling via an interaction with either Gq protein coupling and formation of the second messenger inositol trisphosphate (IP3), or through triggering the effector {beta}-arrestin2. Central to the IP3 pathway is mobilisation of Ca2+ stored in the endoplasmic reticulum (ER). Here, we report the unexpected discovery that the 5-HT2A receptor also signals via an additional second messenger, nicotinic acid adenine dinucleotide phosphate (NAADP), which mobilises Ca2+ release from lysosomal stores. This effect was revealed through measurement of changes in cellular NAADP levels, pharmacological inhibition of NAADP and direct biosensor measurement of lysosomal Ca2+ release and was produced not only by 5-HT but also by a range of psychedelic drugs in a receptor-specific manner. Moreover, genetic ablation of the NAADP pathway reduced markers of both hallucinogenic and neuroplastic effects of psychedelic drug administration in mouse models. These findings reveal the involvement of a novel, therapeutically relevant signalling pathway in psychedelic drug action.

Main resultThe abstract does not state a limitation.

In plain words AI summary

Psychedelic drugs may help treat neuropsychiatric disorders by acting on the 5-HT2A receptor. Scientists found this receptor also uses a second messenger called NAADP. This pathway was found in cells treated with serotonin and various psychedelic drugs. Blocking this pathway in mice reduced hallucinogenic and brain-changing effects of psychedelics.

Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source. 1 sentence was removed for not being supported by the abstract.

Appeared: Wednesday, November 4. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.10.29.762736